The role of staging in multiple myeloma

References

• Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854. PMID: 1182674. doi: 10.1002/1097-0142(197509)
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412–3420. doi: 10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Hari PN, Zhang MJ, Roy V, et al. D. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009;23(8):1528–1534. doi: 10.1038/leu.2009.61
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109. doi: https://doi.org/10.1038/s41408-018-0141-0
   PubMed Web of Science ®Google Scholar
• Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539–1543. doi: 10.1016/j.ejca.2005.11.037
   PubMed Web of Science ®Google Scholar
• Fechtner K, Hillengass J, Delorme S, et al. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 2010;257(1):195–204. doi: 10.1148/radiol.10091809
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International myeloma Working group. JCO. 2015;33(26):2863–2869. doi: 10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–477. doi: 10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Cho H, Yoon DH, Lee JB, et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017;92(12):1280–1286. doi: 10.1002/ajh.24891
   PubMed Web of Science ®Google Scholar
• Gastinne T, Leleu X, Duhamel A, et al. Intergroupe francophone du myelome (IFM). Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol. 2007;79(4):297–304. doi: 10.1111/j.1600-0609.2007.00915.x
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(34):3406–3418. doi: 10.1200/JCO.21.02614
   PubMed Web of Science ®Google Scholar
• Cho HJ, Jung SH, Jo JC, et al. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. Blood Cancer J. 2021;11(12):190. doi: https://doi.org/10.1038/s41408-021-00577-2
   PubMed Web of Science ®Google Scholar
• Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. doi: 10.1038/s41408-022-00611-x
   PubMed Web of Science ®Google Scholar
• Kuiper R, Zweegman S, van Duin M, et al. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Adv. 2020;4(24):6298–6309. doi: 10.1182/bloodadvances.2020002838
   PubMed Web of Science ®Google Scholar
• Mosquera Orgueira A, González Pérez MS, Arias JÁ D, et al. Prognostic stratification of multiple myeloma using clinicogenomic models: Validation and performance analysis of the IAC-50 model. Hemasphere. 2022;6(8):e760. doi: 10.1097/HS9.0000000000000760
   PubMed Web of Science ®Google Scholar
• Allegra A, Tonacci A, Sciaccotta R, et al. Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection. Cancers. 2022;14(3):606. doi: 10.3390/cancers14030606
   PubMed Web of Science ®Google Scholar
• Farswan A, Gupta A, Gupta R, et al. AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario. Transl Oncol. 2021;14(9):101157. Epub 2021 Jul 8. PMID: 34247136; PMCID: PMC8278429. doi: 10.1016/j.tranon.2021.101157
   PubMed Web of Science ®Google Scholar
• Mosquera Orgueira A, González Pérez MS, Diaz Arias J, et al. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish myeloma group. Blood Cancer J. 2022;12:76. doi: 10.1038/s41408-022-00647-z
   PubMed Web of Science ®Google Scholar
• Mosquera Orgueira A, González Pérez MS, Arias JÁ D, et al. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021;35(10):2924–2935. Epub 2021 May 18. PMID: 34007046. doi: 10.1038/s41375-021-01286-2
   PubMed Web of Science ®Google Scholar
• Ban C, Yang F, Wei M, et al. Integrative analysis of gene expression through one-class logistic regression machine learning identifies stemness features in multiple myeloma. Front Genet. 2021;12:666561. doi: 10.3389/fgene.2021.666561
   PubMed Web of Science ®Google Scholar
• Filonzi G, Mancuso K, Zamagni E, et al. A comparison of different staging systems for multiple myeloma: can the MRI pattern play a prognostic role? Am J Roentgenol. 2017;209(1):152–158. doi: 10.2214/AJR.16.17219
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734. doi: 10.1002/ajh.24402
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2023). [cited 2023 Mar 27]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
   Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322. doi: 10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Sive J, Cuthill K, Hunter H, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK myeloma Forum Guideline. Br J Haematol. 2021;193(2):245–268. doi: 10.1111/bjh.17410
   PubMed Web of Science ®Google Scholar
• Marcon C, Simeon V, Deias P, et al. Experts’ consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2023;12:1096852. doi: 10.3389/fonc.2022.1096852
   PubMed Web of Science ®Google Scholar
• Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol. 2014;7(1):21–31. doi: 10.1586/17474086.2014.882224
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–376. doi: 10.1016/j.mayocp.2013.01.019
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi: 10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Premkumar V, Pan S, Lentzsch S, et al. Use of daratumumab in high risk multiple myeloma: A meta-analysis. eJHaem. 2020;1(1):267–271. doi: 10.1002/jha2.47
   PubMedGoogle Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45–e54. doi: 10.1016/S2352-3026(20)30354-9
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. doi: 10.1038/s41408-020-00359-2
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82(3):323–341. doi: 10.4065/82.3.323
   PubMed Web of Science ®Google Scholar
• Cook G, Royle KL, O’Connor S, et al.; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF myeloma X relapse [intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019;185(3):450–467. doi: 10.1111/bjh.15782
   PubMed Web of Science ®Google Scholar
• Tan C, Nemirovsky D, Derkach A, et al. Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma. 64 ASH Annual Meeting Oral Abstract, Dec 10-13, 2022, New Orleans, Louisiana. Session: 652. #752. Available from: https://ash.confex.com/ash/2022/webprogram/Paper169161.html
   Google Scholar
• Panopoulou A, Easdale S, Ethell M, et al. Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients. Hemasphere. 2023;7(2):e831. doi: 10.1097/HS9.0000000000000831
   PubMed Web of Science ®Google Scholar
• Davies FE, Pawlyn C, Saad Z, et al. Perspectives on the risk-stratified treatment of multiple myeloma. Blood Cancer Discov. 2022;3(4):273–284. doi: 10.1158/2643-3230.BCD-21-0205
   PubMedGoogle Scholar
• Moreau P, Attal M, Garban F, et al.; IFM Group. Heterogeneity of t(4;14) in multiple myeloma. long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007;21(9):2020–2024.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International staging system classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150–1157. doi: 10.3324/haematol.2009.016436
   PubMed Web of Science ®Google Scholar
• Boyd KD, Ross FM, Chiecchio L, et al. NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia. 2012;26(2):349–355. doi: 10.1038/leu.2011.204
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Durie BG, Cavo M, et al.; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International myeloma Working group collaborative project. Leukemia. 2013;27(3):711–717.
   PubMed Web of Science ®Google Scholar
• Schmidt TM. High or low? Assessing disease risk in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2022;2022(1):349–355. doi: 10.1182/hematology.2022000347
   PubMedGoogle Scholar
• Bonello F, Cani L, D’Agostino M. Risk stratification before and during treatment in newly diagnosed multiple myeloma: from clinical trials to the real-world setting. Front Oncol. 2022;12:830922. PMID: 35356221; PMCID: PMC8959380. doi: 10.3389/fonc.2022.830922
   PubMed Web of Science ®Google Scholar
• Fan H, Yan W, Li L, et al. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma. Hematology. 2023;28(1):2182156. PMID: 36815749. doi: 10.1080/16078454.2023.2182156
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al. International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277. doi: 10.1038/leu.2013.247
   PubMed Web of Science ®Google Scholar
• Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022;139(19):2889–2903. doi: 10.1182/blood.2020008733
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi: 10.1038/leu.2013.313
   PubMed Web of Science ®Google Scholar
• Tandon N, Rajkumar SV, LaPlant B, et al. Clinical utility of the revised International staging system in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7:e528. doi: 10.1038/bcj.2017.13
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, D’Souza A, Scott E, et al. Revised International staging system is predictive and prognostic for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. Biol Blood Marrow Transplant. 2019;25(4):683–688. doi: 10.1016/j.bbmt.2018.12.141
   PubMed Web of Science ®Google Scholar
• Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, et al. Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(7):445–452. doi: 10.1016/j.clml.2019.10.014
   PubMed Web of Science ®Google Scholar
• Beksac M, Iacobelli S, Koster L, et al. A novel early relapse prediction score based on age, ISS and disease status at the time of transplant in patients with newly diagnosed multiple myeloma. A study of the EBMT chronic malignancies working party. Blood. 2021;138(Supplement 1):3937. doi: 10.1182/blood-2021-147001
   Google Scholar
• Szita VR, Mikala G, Kozma A, et al. Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers. Pathol Oncol Res. 2022;28(28):1610276. doi: 10.3389/pore.2022.1610276
   PubMedGoogle Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in Previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600–1609. doi: 10.1200/JCO.21.02734
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464. doi: 10.1182/blood-2018-06-858613
   PubMed Web of Science ®Google Scholar
• Fonseca R, Arribas M, Wiedmeier-Nutor JE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13(1):32. doi: 10.1038/s41408-023-00794-x
   PubMed Web of Science ®Google Scholar
• Paiva B, Puig N, Cedena M-T, et al.; on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–792.
   PubMed Web of Science ®Google Scholar
• Sun Q, Li X, Gu J, et al. Prognostic significance of the stage at which an MRD-negative status is achieved for patients with multiple myeloma who received ASCT. Front Oncol. 2022;12:776920. doi: 10.3389/fonc.2022.776920
   PubMedGoogle Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754. doi: 10.1001/jamaoncol.2015.2010
   PubMed Web of Science ®Google Scholar
• Wester R, van der Holt B, Asselbergs E, et al. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 2019;104(11):2265–2273. doi: 10.3324/haematol.2018.205476
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA MA, Sonneveld P, Leung N, et al. International myeloma Working group Recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557. doi: 10.1200/JCO.2015.65.0044
   PubMed Web of Science ®Google Scholar
• Yavorkovsky LL, Jing W, Baker R. An upsurge of the serum free light chains as a possible missing link in tumor lysis syndrome in multiple myeloma. Br J Haematol. 2020;188(5):732–735. doi: 10.1111/bjh.16231
   PubMed Web of Science ®Google Scholar
• Yavorkovsky LL, Hope A. A tale of two immunodeficiencies: a case of multiple myeloma associated with profound immune defect mimicking a common variable immune deficiency syndrome. Perm J. 2020;24:19.104. doi: 10.7812/TPP/19.104
   PubMedGoogle Scholar
• Durie BG, Jacobson J, Barlogie B, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22(10):1857–1863. doi: 10.1200/JCO.2004.05.111
   PubMed Web of Science ®Google Scholar
• Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361–375. doi: 10.1111/j.1365-2141.1982.tb02791.x
   PubMed Web of Science ®Google Scholar
• Hokamp HG, Grundmann E. Histological grading and clinical staging of plasmacytoma. J Cancer Res Clin Oncol. 1983;105(2):197–198. doi: 10.1007/BF00406934
   PubMed Web of Science ®Google Scholar
• Greipp PR, Lust JA, O’Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]. Blood. 1993;81(12):3382–3387. doi: 10.1182/blood.V81.12.3382.3382
   PubMed Web of Science ®Google Scholar
• Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group. Blood. 1998;91(7):2501–2507. ISSN 0006-4971. doi: 10.1182/blood.V91.7.2501
   PubMed Web of Science ®Google Scholar
• Witzig T, Timm M, Larson D, et al. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999;104(1):131–137. doi: 10.1046/j.1365-2141.1999.01136.x
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Passam FH, Kyriakou DS, et al. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004;27(1):8–13. doi: 10.1097/01.coc.0000045810.91816.41
   PubMed Web of Science ®Google Scholar
• Robinson MM, Atrash S, Brown T, et al. Prognostic significance of Ki67 expression by immunohistochemistry (IHC) on bone marrow biopsy in newly diagnosed multiple myeloma. Blood. 2017;130(Supplement 1):4348. doi: 10.1182/blood.V130.Suppl_1.4348.4348
   Google Scholar
• Suzuki K, Nishiwaki K, Yano S. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. Cancers (Basel). 2021 8;13(2):215. doi: 10.3390/cancers13020215
   PubMed Web of Science ®Google Scholar
• Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12(5):83. doi: 10.1038/s41408-022-00679-5
   PubMed Web of Science ®Google Scholar